Assessing the level of programmed death ligand 1 (PD-L1) expressed by a non–small-cell lung (NSCLC) tumor can help clinicians determine how the patient should be treated. Now, researchers report (“A Novel Approach to Detect Programmed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non–Small-Cell Lung Cancer (NSCLC) Bronchoscopy Specimen”) in the […]